To test this hypothesis and the impact of different structural organization of distinct conformers of AD brain-derived tau, we introduced a new photochemical hydroxylation footprinting protocol monitored with a panel of Eu-labeled antibodies. The gene discussed is MAPT; the disease is Alzheimer disease.